Bad bugs, new drugs: The antimicrobial peptide C14R is active against the ESKAPE pathogens

The global rise of antimicrobial resistance among the ESKAPE pathogens represents a major challenge to public health. Here, we report the broad-spectrum antibacterial activity of the synthetic antimicrobial and pore-forming peptide C14R against all six ESKAPE species. Using a radial diffusion assay and resazurin-based viability testing, C14R exhibited potent bactericidal effect with minimum inhibitory concentrations (MICs), defined as the lowest concentration of an antimicrobial agent that completely inhibits visible growth of planktonic microorganisms, ranging from 3.4 g/mL (Enterococcus faecium, vancomycin-resistant) to 45.2 g/mL (Klebsiella quasipneumoniae, ESBL). C14R also inhibited biofilm formation by Gram-positive pathogens, with minimum biofilm inhibitory concentrations (MBICs), referring to the minimal concentration required to prevent the development of biofilms, of 15.0 g/mL (Staphylococcus aureus, MRSA) and 22.0 g/mL (E. faecium, VRE), whereas Gram-negatives biofilms showed higher tolerance. Together, these findings demonstrate that C14R retains high activity against multidrug-resistant ESKAPE strains, highlighting its potential as a lead compound for the development of next-generation antimicrobial drugs to expand the portfolio of available antibiotics and brace health systems against emerging severe infections. Author summaryAntibiotic-resistant infections are a growing threat worldwide. A small group of hospital-associated bacteria is especially problematic because they often evade multiple drugs and cause hard-to-treat infections. In this study, we tested the designed antimicrobial peptide C14R as a novel and effective way to fight these bacteria. Peptides are short protein fragments with the ability to puncture and disrupt microbial membranes. We evaluated C14R against six hospital related priority species (so called ESKAPE pathogens) and measured its ability to stop growth and to limit biofilm formation. C14R killed every species we tested and reduced biofilm of two bacteria. Our findings identify C14R as a promising lead for new treatments, particularly for difficult infections and those involving biofilms.